Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd PharmaphorumBoehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.RespiratoryRead full story pharminent July 9, 2026 (Last updated: July 9, 2026) Pharmaphorum Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK. Respiratory Read full story Post navigation Previous: FDA Warning Letter Hits Sanofi’s Genzyme Ireland SiteNext: NICE aims to cut funding for Amgen lung cancer drug Lumykras Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026